Filing Flows › PTC Therapeutics (PTCT) › Collaboration and license revenue revenue
PTC Therapeutics (PTCT) Collaboration and license revenue revenue by quarter
PTC Therapeutics' Collaboration and license revenue revenue was $229K in Q3 2026 (third quarter 2026), -100% from Q2 2026. Over the last 6 quarters it ranged from $143K (Q1 2026) to $986M (Q1 2025).
| Quarter | Collaboration and license revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $229K | -100% | -98% |
| Q2 2026 | $50.6M | 354× | 17× |
| Q1 2026 | $143K | -98% | -100% |
| Q3 2025 | $9.3M | +215% | — |
| Q2 2025 | $2.9M | -100% | — |
| Q1 2025 | $986M | — | — |
Q3 2026 at a glance
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is PTC Therapeutics' Collaboration and license revenue revenue?
PTC Therapeutics' Collaboration and license revenue revenue was $229K in Q3 2026 (third quarter 2026), -100% from Q2 2026.
How has PTC Therapeutics' Collaboration and license revenue revenue changed?
Over the last 6 quarters it ranged from $143K (Q1 2026) to $986M (Q1 2025).